Drug intelligence / Profile preview

citalopram

Development stage
Approved
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

**Description:** Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant used primarily to treat depression and major depressive disorder. It works by increasing the amount of serotonin in the brain, which helps maintain mental balance and improve mood. Citalopram is considered one of the most selective SSRIs, with minimal effects on dopamine and norepinephrine transporters and little affinity for other receptors such as muscarinic, histaminergic, or GABAergic receptors. It does not inhibit monoamine oxidase. The drug is available as tablets, oral solution, and capsules[1][2][3][5]. Developed originally by H. Lundbeck A/S in Denmark[7], citalopram has been marketed globally under various brand names.

Brand names
CelexaCelapramCelicaCiazilCilateCiliftCimalCipralexCipramCipramilCinapenCiprapineCiprotanCitabaxCitaxinCitalCitalecCitalexCitaloCitoxCitrolCittaDalsanDenylDepramElopramEstarHumorupHumorapLopraxerOropramOpraPramPramcitProcimaxRecitalSepramSeropramSzetaloTalamTemperaxVodelaxZentiusZetaloZylotexAkarin
Other names
citalopram hydrobromide
02

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on citalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on citalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call